Search Trulicity (type in keywords)
Search Medical Information
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Trulicity ® (dulaglutide) injection
0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3mg/0.5mL, 4.5mg/0.5mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can patients continue sulfonylureas or insulin on starting Trulicity® (dulaglutide)?
Consider reducing insulin/insulin secretagogue dose when initiating dulaglutide.
US_cFAQ_GLP023_CONCOMITANT_SULFONYLUREA_OR_INSULIN_DOSE
en-US
See important safety information, including boxed warning, in the attached prescribing information.
Detailed Information
To reduce the risk of hypoglycemia when initiating dulaglutide treatment, consider reducing the dosage of concomitantly administered
- insulin secretagogues, such as sulfonylureas, or
- insulin.1
Enclosed Prescribing Information
Reference
1Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
Date of Last Review: July 11, 2023
Are you satisfied with this content?